OLIVIA NEWTON-JOHN CANCER RESEARCH INSTITUTE
- Country
- 🇦🇺Australia
- Ownership
- Private
- Established
- 2014-01-01
- Employees
- 101
- Market Cap
- -
- Website
- http://www.onjcri.org.au
Clinical Trials
12
Trial Phases
3 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (12 trials with phase data)• Click on a phase to view related trials
Treatment of Newly-diagnosed Follicular Lymphoma with CELMoD Golcadomide, Rituximab +/- Nivolumab.
- Conditions
- Follicular Lymphoma Stage IIIFollicular Lymphoma Stage IVFollicular Lymphoma Stage II
- Interventions
- First Posted Date
- 2023-03-28
- Last Posted Date
- 2025-03-21
- Lead Sponsor
- Olivia Newton-John Cancer Research Institute
- Target Recruit Count
- 40
- Registration Number
- NCT05788081
- Locations
- 🇦🇺
Grampians Health, Ballarat, Victoria, Australia
🇦🇺Eastern Health, Box Hill, Victoria, Australia
🇦🇺University Hospital Geelong, Barwon Health, Geelong, Victoria, Australia
A Prospective, Multi-Centre Trial of TKI Redifferentiation Therapy in Patients With RAIR Thyroid Cancer (I-FIRST Study)
- First Posted Date
- 2022-01-10
- Last Posted Date
- 2023-10-31
- Lead Sponsor
- Olivia Newton-John Cancer Research Institute
- Target Recruit Count
- 80
- Registration Number
- NCT05182931
- Locations
- 🇦🇺
Royal North Shore Hospital, Sydney, New South Wales, Australia
🇦🇺Royal Brisbane and Women's Hospital, Brisbane, Queensland, Australia
🇦🇺Royal Adelaide Hsopital, Adelaide, South Australia, Australia
Combination Immunotherapy in Rare Cancers Under InvesTigation
- Conditions
- Advanced Biliary Tract CancerMSI-H Solid Malignant TumorNeuroendocrine TumorsFemale Reproductive System Neoplasm
- Interventions
- First Posted Date
- 2021-07-21
- Last Posted Date
- 2024-03-08
- Lead Sponsor
- Olivia Newton-John Cancer Research Institute
- Target Recruit Count
- 240
- Registration Number
- NCT04969887
- Locations
- 🇦🇺
Border Medical Oncology Unit, Albury, New South Wales, Australia
🇦🇺Orange Health Service, Orange, New South Wales, Australia
🇦🇺Blacktown Hospital, Sydney, New South Wales, Australia
Frontline Treatment of Follicular Lymphoma with AtezolizUmab and Obinutuzumab with and Without RadiOtherapy
- Conditions
- Follicular Lymphoma
- Interventions
- Radiation: 4 Gy in 2 fractions
- First Posted Date
- 2021-07-14
- Last Posted Date
- 2025-03-21
- Lead Sponsor
- Olivia Newton-John Cancer Research Institute
- Target Recruit Count
- 15
- Registration Number
- NCT04962126
- Locations
- 🇦🇺
Ballarat Health Service, Ballarat, Victoria, Australia
🇦🇺Eastern Health, Box Hill, Victoria, Australia
🇦🇺Austin Health, Heidelberg, Victoria, Australia
Bioimaging Study of 89Zr-M7824 in NSCLC
- Conditions
- Non-Small Cell Lung Cancer
- Interventions
- Combination Product: 89Zirconium-M7824
- First Posted Date
- 2020-03-05
- Last Posted Date
- 2023-01-17
- Lead Sponsor
- Olivia Newton-John Cancer Research Institute
- Target Recruit Count
- 5
- Registration Number
- NCT04297748
- Locations
- 🇦🇺
Austin Health, Heidelberg, Victoria, Australia
- Prev
- 1
- 2
- Next
News
Ribociclib (Kisqali) Added to PBS for Early-Stage Breast Cancer Patients in Australia
Ribociclib (Kisqali) is now subsidized on Australia's Pharmaceutical Benefits Scheme for early-stage breast cancer patients with hormone receptor-positive, HER2-negative disease at high risk of recurrence.